Related Experiment Videos
Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study
1Department of Surgery II, Osaka University Medical School, Japan.
Anticancer Research
|January 1, 1996
Summary
The plasminogen activation system, including urokinase-type plasminogen activator (uPA), is active in thyroid tumors but doesn't significantly alter their characteristics or prognosis. This system also appears to promote benign tissue growth.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The plasminogen activation system (PAS) is implicated in tumor progression, enhancing metastasis and invasion.
- Understanding PAS expression in thyroid tumors is crucial for comprehending tumor behavior.
Purpose of the Study:
- To investigate the expression and localization of key PAS components in clinical thyroid tumors.
- To correlate PAS protein expression with clinicopathological parameters in thyroid carcinoma.
Main Methods:
- Immunohistochemical analysis of thyroid carcinoma tissues.
- Assessment of urokinase-type plasminogen activator (uPA), its receptor (uPAR), plasminogen activator inhibitor type 1 (PAI-1), and plasminogen activator inhibitor type 2 (PAI-2) expression.
- Correlation of protein expression with clinicopathological data.
Main Results:
- uPA, uPAR, and PAI-1 were diffusely expressed in most thyroid carcinomas.
- PAI-2 expression was variable, with only 56% of carcinomas showing diffuse immunoreactivity.
- No significant relationship was found between PAS component expression and clinicopathological parameters.
Conclusions:
- The PAS is functionally active in thyroid carcinoma but has minimal impact on general characteristics like growth and prognosis.
- PAS components are also expressed in benign thyroid tissues, potentially contributing to their growth.
- Differential expression patterns of PAI-1 and PAI-2 suggest distinct roles in thyroid tumorigenesis.